The Real-World Experience Of Rfviii-Fc Used In Hemophilia A Patients In Taiwan: Prophylaxis Rates, Pharmacokinetics And Clinical Correlates, And The Effects On Joint Health

Introduction: Routine prophylaxis (RP) has been a standard therapeutic strategy for person with hemophilia (PWH) since 2007. However, frequent injection resulting in patients' burden decreased rates of RP. Extended half-life (EHL) product rFVIII-Fc can reduce the injection burden of RP compared with standard half-life (SHL) rFVIII and was started to be used in Taiwan since November, 2018. The reports of real-world pharmacokinetics (PK) and clinical experience of rFVIII-Fc in Asian countries were relatively few. We aimed to share our clinical experience of rFVIII-Fc for previously-treated patients (PTP) with hemophilia A iin Taiwan.